Priscilla Benewaah
Family · Rosedale, MDNPI 1053715508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $571 and has fallen 81.4% since, to $107 in 2025.
Across 68 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$264
- Indivior Inc.$217
- AbbVie$208
- Corium, LLC$170
- Teva Pharmaceuticals USA, Inc.$138
- Alkermes, Inc.$132
- plus $302 from 6 others
What the payments were for
- Food & beverage$1,431100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $264 |
| Indivior Inc. | 10 | $217 |
| AbbVie | 11 | $208 |
| Corium, LLC | 3 | $170 |
| Teva Pharmaceuticals USA, Inc. | 6 | $138 |
| Alkermes, Inc. | 6 | $132 |
| Orexo US, Inc. | 8 | $117 |
| Neurocrine Biosciences, Inc. | 5 | $89 |
| Tris Pharma Inc | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $22 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azstarys$105
How this compares
$1,431 in reported general payments places this provider in the 75th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 13 | $732 |
| Mirtazapine | 13 | $546 |
| Divalproex Sodium | 11 | $526 |
| Latanoprost | 12 | $429 |
| Gabapentin | 12 | $375 |
| Clonazepam | 11 | $285 |
| Amlodipine Besylate | 13 | $195 |
| Hydrochlorothiazide | 12 | $165 |
| Zolpidem Tartrate | 12 | $110 |
Paid to pharmacies, not to this prescriber.
Other family in Rosedale
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.